| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
X-Chem's DNA-encoded library complements Charles River's discovery expertise to accelerate hit identification
Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics. This partnership enables Charles River clients to access X-Chem's DEL platform, which features a proprietary library of over 15 billion compounds.
The collaboration combines Charles River's in-house protein production and downstream assay development, along with decades of hit ID expertise, with X-Chem's industry-leading DEL platform, creating a seamless workflow from hit identification to Hit-to-Lead optimization. Charles River has a broad suite of hit ID services that can deliver high-quality, validated hit compounds for drug discovery projects. With this complete offering, these designs and approaches will deliver the most impactful hits to support biopharma research goals and drug development plans.
Posted In: CRL
